Melanocortin and dermal research
PT-141
Lyophilized dermal or melanocortin research peptide
PT-141 / bremelanotide is a melanocortin receptor research peptide studied around central melanocortin signaling.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesPour la recherche en laboratoire uniquement. Pas pour un usage humain ou vétérinaire. Non destiné à diagnostiquer, traiter, guérir, atténuer ou prévenir une maladie.
Conserver scellé, froid, sec et protégé des variations de chaleur. Confirmez le stockage spécifique au produit à l'arrivée.
Emballé pour la stabilité du transit avec une assistance aux commandes disponible pour les itinéraires par temps chaud.
Batch-linked certificate support is available through the documentation desk.
Contexte de recherche
Profil de recherche PT-141
PT-141, also known as bremelanotide in pharmaceutical literature, is a cyclic melanocortin receptor agonist studied primarily for central melanocortin signaling. Research examines receptor pharmacology, neural pathway activation, behavioral endpoints, pharmacokinetics, and differences from pigment-focused alpha-MSH analogs. It is related to Melanotan II by molecular lineage but is generally selected when the study centers on central signaling rather than melanogenesis. Human pharmaceutical studies provide a developed evidence context for regulated bremelanotide products, but those data do not establish the identity, approval, safety, or performance of a research-use catalog batch. Product selection should remain based on the molecular reference, format, and documentation.
Mécanisme proposé
A cyclic melanocortin receptor agonist developed from the Melanotan II lineage. Proposed effects are primarily central and involve MC3R/MC4R-related neural circuits rather than a direct vascular mechanism.
Effets rapportés dans les études
- Animal studies report activation of central melanocortin pathways and sexual-response behaviors.
- Controlled human studies of regulated bremelanotide reported changes in sexual-desire or distress endpoints in selected populations.
- Nausea, flushing, headache, transient blood-pressure increases, and hyperpigmentation are important reported effects.
Critères de recherche courants
Melanocortin receptor potency, neural activation, behavioral response, validated desire and distress scores, blood pressure, heart rate, nausea, pigmentation, and pharmacokinetics.
Preuves et limites
Preclinical and controlled human evidence exists for regulated bremelanotide. Research material is not represented as equivalent to an approved drug product.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.